Insight

Elad Sharon: Quite promising for c-MET over-expressing NSCLC

Photo from Elad Sharon/X

Aug 29, 2024, 17:01

Elad Sharon: Quite promising for c-MET over-expressing NSCLC

Elad Sharon, Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Giuseppe Banna, Consultant Medical Oncologist at Portsmouth Hospitals University NHS Trust, adding:

“Wow! This looks quite promising for c-MET over-expressing NSCLC! Let the march of ADCs continue in oncology!”

Quoting Giuseppe Banna’s post:

“The Phase II LUMINOSITY trial shows promising results for Telisotuzumab Vedotin in treating c-Met protein–overexpressing advanced NSCLC, especially in patients with high c-Met expression.”

Giuseppe Banna

“Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR-Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.”

Authors: Ross Camidge, Jair Bar, Hidehito Horinouchi, Christine Ratajczak, Shun Lu et al.

Giuseppe Banna

Sources: Elad Sharon/X and Giuseppe Banna/X

ADC cancer Christine Ratajczak Dana-Farber Cancer Institute Elad Sharon Giuseppe Banna Hidehito Horinouchi Jair Bar LUMINOSITY trial NSCLC OncoDaily Oncology Portsmouth Hospitals University NHS Trust Ross Camidge Shun Lu Telisotuzumab Vedotin

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

China Anti-Cancer Association (CACA) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care

Donald Trump: Thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of HHS

Overview of ASCO Breakthrough

Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More

Special Coverage